Growth patterns in children with the salt-losing variety of congenital adrenal hyperplasia have been studied by various authors (Bergstrand, 1966; Laron and Pertzelan, 1968;  Rappaport, Cornu, and Royer, 1968; Sperling et al., 1971; Stempfel et al., 1968) . Most investigators have found that there is a growth failure in this group of children related to the growth retarding effects of the steroid therapy which they have received (Raiti and Newns, 1970) .
In an attempt to prevent such growth failure, various treatment schedules have been recommended (Bergstrand, 1966; Blodgett et al., 1956; Laron and Pertzelan, 1968; Migeon, 1968; Rappaport et al., 1968; Sperling et al., 1971; Stempfel et al., 1968) . The optimal dosage of steroid for pituitary suppression with minimal growth inhibition that has been recommended varies from 30 to 40 mg hydrocortisone/m2 per day by Sperling et al. (1971) to 12 to 36 mg by Migeon (1968) .
In the first year of life regular administration of an oral steroid preparation presents difficulties such as vomiting and refusal to take the preparation, and frequent intramuscular injections are painful and time consuming. Long-acting steroid preparations given by intramuscular injection at monthly intervals have been used in an attempt to avoid these problems. However, various series have been reported in which the long-acting hormone preparations have been shown to have more growth Received 26 June 1973, 4 inhibiting effect than hydrocortisone (Laron and Pertzelan, 1968; Stempfel et al., 1968) . Laron and Pertzelan reviewed the growth of 6 children who had been treated interchangeably with 6-a-methylprednisolone, 6-ac-fluroprednisolone, and hydrocortisone. They found that in this group hydrocortisone permitted normal linear growth while 6-ac-methyl-and 6-a-fluroprednisolone both caused growth retardation. Stempfel et al. studied pituitary growth hormone secretion in 7 patients who received 6-a-methylprednisolone. They found that the normal response to insulin-induced hypoglycaemia was depressed in these patients, and that it was restored by changing their therapy to hydrocortisone. Vazquez, Schutt-Aine, and Kenny (1972) studying a child treated with intramuscular and oral cortisone, and Sturge et al. (1970) studying children treated with prednisolone, did not find any growth hormone suppression in their patients.
Patients and methods The group consisted of 16 girls and 4 boys. Their ages at the time of the survey ranged from 1 year 6 months to 17 years 4 months. Therapy had started in the first month of life in 17 cases, at 3 months in 2 cases, and at 81 months in 1. With the exception of 4 children who were diagnosed at other centres, the condition was first brought under control using short-acting preparations of deoxycorticosterone acetate (DOCA) and hydrocortisone, and then was continued by using The skeletal age of the children in this group is similarly retarded with respect to chronological age, i.e. there is a disparity of 6 months or more in 13 out of the 20 children. Skeletal age is equivalent to chronological age in 4 children and is in advance in 3 children.
It is of interest to note that in the 11 children who are below the 3rd centile for height, skeletal age is retarded in 9.
An attempt has been made to relate these findings to the therapy which this group of children received in the first year of life, as it is in this respect that they differ from most other groups so far reported. 14 children received PTMA and all except one of these these data. The majority of the children received the equivalent of between 10 and 20 mg hydrocortisone/M2 per day. The height velocities are clustered around the 50th centile. It is of significance that the one child who is below the 3rd centile received the highest dose of PTMA in the group. There are 2 children above the 97th centile and this probably indicates that they were undertreated during this period. The 6 children who were treated with oral short-acting steroid preparations are stunted in height and have retarded skeletal ages: 4 of these children lie below the 3rd centile for height, 1 lies on the 10th, and 1 on the 25th. If the steroid which they received is expressed in terms of its hydrocortisone equivalent per m2 per day in the same way as the first group, it is apparent that these children received considerably more steroid than the children given long-acting steroid. In this group of 6 older children, therefore, 4 are below the 3rd centile for height, 1 is on the 10th centile and 1 on the 25th centile. All but one have retarded bone ages. This is the situation that one expects to see in steroid overdosage. delayed skeletal maturation, which could be due to the effect of the steroid which they have received.
The dose of steroid they received when expressed in terms of its equivalent dose of hydrocortisone was well within the limits prescribed by Migeon (1968) and below those of Sperling et al. (1971) and Rappaport et al. (1968) , both in the first year of life and subsequently. However, Blodgett et al. (1956) reported that doses of hydrocortisone between 14 and 20 mg/M2 per day could produce marked growth inhibition and delayed skeletal maturation, and our dosage was certainly within or above such levels.
These children received a long-acting prednisone analogue in the first year of life and there is some evidence to suggest that such compounds cause more growth retardation than hydrocortisone. In the doses we have used there does not appear to have been any reduction of growth velocity in the first year of life in this group of children. The one child who did not achieve a normal velocity was given higher dosage and this suggests that, like most of the steroid drugs, the stunting effect of PTMA is dose related. This child's present height is on the 3rd centile. This regimen therefore provided an easily regulated reliable method of treating the children and does not appear to cause significant stunting.
If this is the case, then subsequent therapy with prednisone appears to have been the prime factor in stunting these children. Prednisone is reported to have a greater stunting effect than hydrocortisone (Van Metre, Niermann, and Rosen, 1960) . Van Metre reported that doses of prednisone up to 6 mg/M2 per day did not have any growth inhibiting effect. All except 3 of our group of children received less than this dose and none received more than 8 mg/m2 per day.
A further possibility is that the children have been overtreated because our criteria for control have been too strict, the acceptable levels of urinary 17-ketosteroid which we have used being slightly lower than those mentioned by Raiti and Newns (1970) . The children with retarded skeletal ages have open epiphyses, and hopefully some catch-up growth will occur with better ultimate height achievement than one would forecast at present.
In conclusion, therefore, we can say that PTMA in the first year of life provides a convenient method of control for children with this condition and in our experience does not influence rate of growth in the first year. Subsequent therapy with prednisone appears to have stunted growth in our group, due either to an effect of the drug itself or to too strict control leading to unnecessarily high dosage. For the future we are considering the use of hydrocortisone to control these children and we may relax our criteria for control while placing greater emphasis on maintaining the rate of skeletal maturation parallel to chronological age. 
